Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
-
Tabernero, Josep (Hospital Universitari Vall d'Hebron)
;
Hozak, Rebecca R (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Yoshino, Takayuki (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ;
Cohn, A. L. (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ;
Obermannova, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ;
Bodoky, G. (St László Hospital (Hongria)) ;
García-Carbonero, Rocío (Universidad Complutense de Madrid) ;
Ciuleanu, Tudor Eliade (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ;
Portnoy, D. C. (Oncology, West Clinic, Memphis, USA) ;
Prausová, J. (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ;
Muro, K. (Aichi Cancer Center Hospital) ;
Siegel, R. W. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ;
Konrad, R. J. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ;
Ouyang, H. (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Melemed, Symantha A (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Ferry, David (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F. (Oncology, Eli Lilly and Company, Argentina) ;
Van Cutsem, E. (KU Leuven, Leuven, Belgium) ;
Universitat Autònoma de Barcelona
visitante ::
identificación
Subscribirse to this discussion. You will then receive all new comments by email.
